nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—Vemurafenib—skin cancer	0.387	0.591	CrCtD
Etoricoxib—Vismodegib—skin cancer	0.268	0.409	CrCtD
Etoricoxib—PTGS2—skin cancer	0.112	1	CbGaD
Etoricoxib—CYP1A2—Imiquimod—skin cancer	0.0231	0.147	CbGbCtD
Etoricoxib—CYP2C19—Vismodegib—skin cancer	0.0173	0.111	CbGbCtD
Etoricoxib—CYP2E1—Dacarbazine—skin cancer	0.0168	0.107	CbGbCtD
Etoricoxib—CYP2C9—Vismodegib—skin cancer	0.0144	0.092	CbGbCtD
Etoricoxib—CYP1A2—Vemurafenib—skin cancer	0.0126	0.0807	CbGbCtD
Etoricoxib—CYP3A4—Imiquimod—skin cancer	0.0121	0.0772	CbGbCtD
Etoricoxib—CYP3A4—Temozolomide—skin cancer	0.0121	0.0772	CbGbCtD
Etoricoxib—CYP2D6—Vemurafenib—skin cancer	0.0104	0.0665	CbGbCtD
Etoricoxib—CYP1A2—Dacarbazine—skin cancer	0.00969	0.0619	CbGbCtD
Etoricoxib—CYP3A4—Vismodegib—skin cancer	0.00838	0.0535	CbGbCtD
Etoricoxib—CYP3A4—Vemurafenib—skin cancer	0.00662	0.0423	CbGbCtD
Etoricoxib—CYP1A2—Fluorouracil—skin cancer	0.00568	0.0363	CbGbCtD
Etoricoxib—CYP2C9—Fluorouracil—skin cancer	0.00512	0.0327	CbGbCtD
Etoricoxib—CYP3A4—Docetaxel—skin cancer	0.00227	0.0145	CbGbCtD
Etoricoxib—Vismodegib—SHH—skin cancer	0.00134	0.444	CrCbGaD
Etoricoxib—MAPK14—hair follicle—skin cancer	0.000986	0.106	CbGeAlD
Etoricoxib—MAPK14—blood vessel—skin cancer	0.000925	0.0995	CbGeAlD
Etoricoxib—Vemurafenib—BRAF—skin cancer	0.000801	0.266	CrCbGaD
Etoricoxib—Vismodegib—SMO—skin cancer	0.000768	0.255	CrCbGaD
Etoricoxib—MAPK14—neck—skin cancer	0.000662	0.0712	CbGeAlD
Etoricoxib—PTGS2—leg—skin cancer	0.000624	0.0671	CbGeAlD
Etoricoxib—PTGS2—hindlimb—skin cancer	0.000557	0.0599	CbGeAlD
Etoricoxib—PTGS2—appendage—skin cancer	0.000478	0.0514	CbGeAlD
Etoricoxib—MAPK14—connective tissue—skin cancer	0.000474	0.051	CbGeAlD
Etoricoxib—MAPK14—epithelium—skin cancer	0.00045	0.0485	CbGeAlD
Etoricoxib—MAPK14—skin of body—skin cancer	0.000428	0.0461	CbGeAlD
Etoricoxib—PTGS2—skin epidermis—skin cancer	0.000398	0.0428	CbGeAlD
Etoricoxib—MAPK14—lymphoid tissue—skin cancer	0.000347	0.0373	CbGeAlD
Etoricoxib—MAPK14—female reproductive system—skin cancer	0.000334	0.036	CbGeAlD
Etoricoxib—PTGS2—endothelium—skin cancer	0.000288	0.031	CbGeAlD
Etoricoxib—MAPK14—head—skin cancer	0.000279	0.0301	CbGeAlD
Etoricoxib—PTGS2—blood vessel—skin cancer	0.000266	0.0286	CbGeAlD
Etoricoxib—CYP1A2—nipple—skin cancer	0.000232	0.025	CbGeAlD
Etoricoxib—MAPK14—lymph node—skin cancer	0.000196	0.0211	CbGeAlD
Etoricoxib—PTGS2—connective tissue—skin cancer	0.000136	0.0147	CbGeAlD
Etoricoxib—PTGS2—epithelium—skin cancer	0.000129	0.0139	CbGeAlD
Etoricoxib—PTGS2—skin of body—skin cancer	0.000123	0.0133	CbGeAlD
Etoricoxib—CYP2C9—female reproductive system—skin cancer	0.00011	0.0119	CbGeAlD
Etoricoxib—CYP2E1—lymphoid tissue—skin cancer	0.000108	0.0117	CbGeAlD
Etoricoxib—CYP2E1—female reproductive system—skin cancer	0.000104	0.0112	CbGeAlD
Etoricoxib—Celecoxib—PTGS2—skin cancer	0.000102	0.034	CrCbGaD
Etoricoxib—PTGS2—lymphoid tissue—skin cancer	9.97e-05	0.0107	CbGeAlD
Etoricoxib—PTGS2—female reproductive system—skin cancer	9.62e-05	0.0104	CbGeAlD
Etoricoxib—CYP2E1—head—skin cancer	8.73e-05	0.00939	CbGeAlD
Etoricoxib—CYP3A4—female reproductive system—skin cancer	8.41e-05	0.00904	CbGeAlD
Etoricoxib—CYP2D6—female reproductive system—skin cancer	8.27e-05	0.0089	CbGeAlD
Etoricoxib—PTGS2—head—skin cancer	8.04e-05	0.00865	CbGeAlD
Etoricoxib—Pruritus—Vemurafenib—skin cancer	7.03e-05	0.00127	CcSEcCtD
Etoricoxib—Connective tissue disorder—Temozolomide—skin cancer	7.02e-05	0.00127	CcSEcCtD
Etoricoxib—Urethral disorder—Temozolomide—skin cancer	7.01e-05	0.00127	CcSEcCtD
Etoricoxib—Alopecia—Dactinomycin—skin cancer	6.98e-05	0.00126	CcSEcCtD
Etoricoxib—Feeling abnormal—Imiquimod—skin cancer	6.98e-05	0.00126	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Imiquimod—skin cancer	6.93e-05	0.00125	CcSEcCtD
Etoricoxib—Epistaxis—Fluorouracil—skin cancer	6.92e-05	0.00125	CcSEcCtD
Etoricoxib—CYP2D6—head—skin cancer	6.91e-05	0.00744	CbGeAlD
Etoricoxib—Visual impairment—Temozolomide—skin cancer	6.89e-05	0.00125	CcSEcCtD
Etoricoxib—Sinusitis—Fluorouracil—skin cancer	6.88e-05	0.00124	CcSEcCtD
Etoricoxib—Erythema—Dactinomycin—skin cancer	6.88e-05	0.00124	CcSEcCtD
Etoricoxib—Gastrointestinal haemorrhage—Docetaxel—skin cancer	6.87e-05	0.00124	CcSEcCtD
Etoricoxib—Pain in extremity—Docetaxel—skin cancer	6.87e-05	0.00124	CcSEcCtD
Etoricoxib—Anaemia—Bleomycin—skin cancer	6.82e-05	0.00123	CcSEcCtD
Etoricoxib—Diarrhoea—Vemurafenib—skin cancer	6.8e-05	0.00123	CcSEcCtD
Etoricoxib—Erythema multiforme—Temozolomide—skin cancer	6.76e-05	0.00122	CcSEcCtD
Etoricoxib—Urticaria—Imiquimod—skin cancer	6.73e-05	0.00122	CcSEcCtD
Etoricoxib—Abdominal pain—Imiquimod—skin cancer	6.7e-05	0.00121	CcSEcCtD
Etoricoxib—Eye disorder—Temozolomide—skin cancer	6.68e-05	0.00121	CcSEcCtD
Etoricoxib—Tinnitus—Temozolomide—skin cancer	6.66e-05	0.00121	CcSEcCtD
Etoricoxib—Flushing—Temozolomide—skin cancer	6.63e-05	0.0012	CcSEcCtD
Etoricoxib—Cardiac disorder—Temozolomide—skin cancer	6.63e-05	0.0012	CcSEcCtD
Etoricoxib—Haemoglobin—Fluorouracil—skin cancer	6.62e-05	0.0012	CcSEcCtD
Etoricoxib—Haemorrhage—Fluorouracil—skin cancer	6.59e-05	0.00119	CcSEcCtD
Etoricoxib—Dizziness—Vemurafenib—skin cancer	6.57e-05	0.00119	CcSEcCtD
Etoricoxib—Hypoaesthesia—Fluorouracil—skin cancer	6.55e-05	0.00119	CcSEcCtD
Etoricoxib—Pharyngitis—Fluorouracil—skin cancer	6.54e-05	0.00118	CcSEcCtD
Etoricoxib—Angiopathy—Temozolomide—skin cancer	6.48e-05	0.00117	CcSEcCtD
Etoricoxib—Immune system disorder—Temozolomide—skin cancer	6.46e-05	0.00117	CcSEcCtD
Etoricoxib—Mediastinal disorder—Temozolomide—skin cancer	6.44e-05	0.00117	CcSEcCtD
Etoricoxib—Cough—Bleomycin—skin cancer	6.44e-05	0.00116	CcSEcCtD
Etoricoxib—Anaemia—Dactinomycin—skin cancer	6.36e-05	0.00115	CcSEcCtD
Etoricoxib—Vomiting—Vemurafenib—skin cancer	6.32e-05	0.00114	CcSEcCtD
Etoricoxib—Alopecia—Temozolomide—skin cancer	6.32e-05	0.00114	CcSEcCtD
Etoricoxib—Chest pain—Bleomycin—skin cancer	6.28e-05	0.00114	CcSEcCtD
Etoricoxib—Orthostatic hypotension—Docetaxel—skin cancer	6.28e-05	0.00113	CcSEcCtD
Etoricoxib—Rash—Vemurafenib—skin cancer	6.26e-05	0.00113	CcSEcCtD
Etoricoxib—Mental disorder—Temozolomide—skin cancer	6.26e-05	0.00113	CcSEcCtD
Etoricoxib—Dermatitis—Vemurafenib—skin cancer	6.26e-05	0.00113	CcSEcCtD
Etoricoxib—Hypersensitivity—Imiquimod—skin cancer	6.24e-05	0.00113	CcSEcCtD
Etoricoxib—Headache—Vemurafenib—skin cancer	6.22e-05	0.00113	CcSEcCtD
Etoricoxib—Malnutrition—Temozolomide—skin cancer	6.22e-05	0.00113	CcSEcCtD
Etoricoxib—Erythema—Temozolomide—skin cancer	6.22e-05	0.00113	CcSEcCtD
Etoricoxib—Breast disorder—Docetaxel—skin cancer	6.21e-05	0.00112	CcSEcCtD
Etoricoxib—Aspartate aminotransferase increased—Docetaxel—skin cancer	6.19e-05	0.00112	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Docetaxel—skin cancer	6.19e-05	0.00112	CcSEcCtD
Etoricoxib—Cramp muscle—Docetaxel—skin cancer	6.19e-05	0.00112	CcSEcCtD
Etoricoxib—Dysgeusia—Temozolomide—skin cancer	6.09e-05	0.0011	CcSEcCtD
Etoricoxib—Asthenia—Imiquimod—skin cancer	6.08e-05	0.0011	CcSEcCtD
Etoricoxib—Confusional state—Bleomycin—skin cancer	6.07e-05	0.0011	CcSEcCtD
Etoricoxib—Alanine aminotransferase increased—Docetaxel—skin cancer	6.06e-05	0.0011	CcSEcCtD
Etoricoxib—Anaphylactic shock—Bleomycin—skin cancer	6.02e-05	0.00109	CcSEcCtD
Etoricoxib—Oedema—Bleomycin—skin cancer	6.02e-05	0.00109	CcSEcCtD
Etoricoxib—Pruritus—Imiquimod—skin cancer	6e-05	0.00108	CcSEcCtD
Etoricoxib—Infection—Bleomycin—skin cancer	5.98e-05	0.00108	CcSEcCtD
Etoricoxib—Nausea—Vemurafenib—skin cancer	5.9e-05	0.00107	CcSEcCtD
Etoricoxib—Thrombocytopenia—Bleomycin—skin cancer	5.89e-05	0.00107	CcSEcCtD
Etoricoxib—Arrhythmia—Fluorouracil—skin cancer	5.88e-05	0.00106	CcSEcCtD
Etoricoxib—Vision blurred—Temozolomide—skin cancer	5.86e-05	0.00106	CcSEcCtD
Etoricoxib—Bronchospasm—Docetaxel—skin cancer	5.84e-05	0.00106	CcSEcCtD
Etoricoxib—Tremor—Temozolomide—skin cancer	5.83e-05	0.00105	CcSEcCtD
Etoricoxib—Alopecia—Fluorouracil—skin cancer	5.82e-05	0.00105	CcSEcCtD
Etoricoxib—Diarrhoea—Imiquimod—skin cancer	5.8e-05	0.00105	CcSEcCtD
Etoricoxib—Angina pectoris—Docetaxel—skin cancer	5.78e-05	0.00105	CcSEcCtD
Etoricoxib—Anaemia—Temozolomide—skin cancer	5.75e-05	0.00104	CcSEcCtD
Etoricoxib—Anorexia—Bleomycin—skin cancer	5.74e-05	0.00104	CcSEcCtD
Etoricoxib—Erythema—Fluorouracil—skin cancer	5.73e-05	0.00104	CcSEcCtD
Etoricoxib—Agitation—Temozolomide—skin cancer	5.72e-05	0.00103	CcSEcCtD
Etoricoxib—Angioedema—Temozolomide—skin cancer	5.69e-05	0.00103	CcSEcCtD
Etoricoxib—PTGS2—lymph node—skin cancer	5.63e-05	0.00605	CbGeAlD
Etoricoxib—Oedema—Dactinomycin—skin cancer	5.61e-05	0.00102	CcSEcCtD
Etoricoxib—Dizziness—Imiquimod—skin cancer	5.6e-05	0.00101	CcSEcCtD
Etoricoxib—Infection—Dactinomycin—skin cancer	5.58e-05	0.00101	CcSEcCtD
Etoricoxib—Palpitations—Temozolomide—skin cancer	5.5e-05	0.000994	CcSEcCtD
Etoricoxib—Thrombocytopenia—Dactinomycin—skin cancer	5.5e-05	0.000994	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Bleomycin—skin cancer	5.48e-05	0.000992	CcSEcCtD
Etoricoxib—Cough—Temozolomide—skin cancer	5.43e-05	0.000982	CcSEcCtD
Etoricoxib—Weight increased—Docetaxel—skin cancer	5.4e-05	0.000977	CcSEcCtD
Etoricoxib—Vision blurred—Fluorouracil—skin cancer	5.4e-05	0.000977	CcSEcCtD
Etoricoxib—Vomiting—Imiquimod—skin cancer	5.39e-05	0.000974	CcSEcCtD
Etoricoxib—Hypertension—Temozolomide—skin cancer	5.37e-05	0.000972	CcSEcCtD
Etoricoxib—Dyspnoea—Bleomycin—skin cancer	5.37e-05	0.000971	CcSEcCtD
Etoricoxib—MAPK14—ATF-2 transcription factor network—CDK4—skin cancer	5.35e-05	0.00672	CbGpPWpGaD
Etoricoxib—Anorexia—Dactinomycin—skin cancer	5.35e-05	0.000968	CcSEcCtD
Etoricoxib—Rash—Imiquimod—skin cancer	5.34e-05	0.000966	CcSEcCtD
Etoricoxib—Dermatitis—Imiquimod—skin cancer	5.34e-05	0.000965	CcSEcCtD
Etoricoxib—Pneumonia—Docetaxel—skin cancer	5.33e-05	0.000963	CcSEcCtD
Etoricoxib—Headache—Imiquimod—skin cancer	5.31e-05	0.00096	CcSEcCtD
Etoricoxib—Anaemia—Fluorouracil—skin cancer	5.3e-05	0.000958	CcSEcCtD
Etoricoxib—Arthralgia—Temozolomide—skin cancer	5.3e-05	0.000958	CcSEcCtD
Etoricoxib—Infestation NOS—Docetaxel—skin cancer	5.29e-05	0.000958	CcSEcCtD
Etoricoxib—Infestation—Docetaxel—skin cancer	5.29e-05	0.000958	CcSEcCtD
Etoricoxib—Anxiety—Temozolomide—skin cancer	5.28e-05	0.000955	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	5.26e-05	0.000951	CcSEcCtD
Etoricoxib—MAPK14—MAPK Cascade—NRAS—skin cancer	5.26e-05	0.0066	CbGpPWpGaD
Etoricoxib—Stevens-Johnson syndrome—Docetaxel—skin cancer	5.25e-05	0.000949	CcSEcCtD
Etoricoxib—Decreased appetite—Bleomycin—skin cancer	5.23e-05	0.000946	CcSEcCtD
Etoricoxib—Acute coronary syndrome—Docetaxel—skin cancer	5.22e-05	0.000944	CcSEcCtD
Etoricoxib—Renal failure—Docetaxel—skin cancer	5.2e-05	0.000941	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Docetaxel—skin cancer	5.19e-05	0.000939	CcSEcCtD
Etoricoxib—Myocardial infarction—Docetaxel—skin cancer	5.19e-05	0.000939	CcSEcCtD
Etoricoxib—Dry mouth—Temozolomide—skin cancer	5.18e-05	0.000937	CcSEcCtD
Etoricoxib—Jaundice—Docetaxel—skin cancer	5.16e-05	0.000933	CcSEcCtD
Etoricoxib—Stomatitis—Docetaxel—skin cancer	5.16e-05	0.000933	CcSEcCtD
Etoricoxib—Pain—Bleomycin—skin cancer	5.15e-05	0.000931	CcSEcCtD
Etoricoxib—Conjunctivitis—Docetaxel—skin cancer	5.15e-05	0.000931	CcSEcCtD
Etoricoxib—Confusional state—Temozolomide—skin cancer	5.12e-05	0.000926	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Dactinomycin—skin cancer	5.12e-05	0.000925	CcSEcCtD
Etoricoxib—Anaphylactic shock—Temozolomide—skin cancer	5.08e-05	0.000918	CcSEcCtD
Etoricoxib—Oedema—Temozolomide—skin cancer	5.08e-05	0.000918	CcSEcCtD
Etoricoxib—Infection—Temozolomide—skin cancer	5.04e-05	0.000912	CcSEcCtD
Etoricoxib—Nausea—Imiquimod—skin cancer	5.03e-05	0.00091	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Docetaxel—skin cancer	5.01e-05	0.000906	CcSEcCtD
Etoricoxib—Epistaxis—Docetaxel—skin cancer	4.99e-05	0.000903	CcSEcCtD
Etoricoxib—Nervous system disorder—Temozolomide—skin cancer	4.98e-05	0.000901	CcSEcCtD
Etoricoxib—Thrombocytopenia—Temozolomide—skin cancer	4.97e-05	0.000899	CcSEcCtD
Etoricoxib—Feeling abnormal—Bleomycin—skin cancer	4.96e-05	0.000897	CcSEcCtD
Etoricoxib—Skin disorder—Temozolomide—skin cancer	4.93e-05	0.000892	CcSEcCtD
Etoricoxib—MAPK14—Regulation of retinoblastoma protein—CDK4—skin cancer	4.89e-05	0.00615	CbGpPWpGaD
Etoricoxib—MAPK14—TSH signaling pathway—CDK4—skin cancer	4.89e-05	0.00615	CbGpPWpGaD
Etoricoxib—Chest pain—Fluorouracil—skin cancer	4.88e-05	0.000883	CcSEcCtD
Etoricoxib—Decreased appetite—Dactinomycin—skin cancer	4.88e-05	0.000883	CcSEcCtD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—RASA1—skin cancer	4.87e-05	0.00611	CbGpPWpGaD
Etoricoxib—Fatigue—Dactinomycin—skin cancer	4.84e-05	0.000875	CcSEcCtD
Etoricoxib—Anorexia—Temozolomide—skin cancer	4.84e-05	0.000875	CcSEcCtD
Etoricoxib—Pain—Dactinomycin—skin cancer	4.8e-05	0.000868	CcSEcCtD
Etoricoxib—Urticaria—Bleomycin—skin cancer	4.78e-05	0.000865	CcSEcCtD
Etoricoxib—Haemoglobin—Docetaxel—skin cancer	4.78e-05	0.000864	CcSEcCtD
Etoricoxib—Hepatitis—Docetaxel—skin cancer	4.75e-05	0.00086	CcSEcCtD
Etoricoxib—Haemorrhage—Docetaxel—skin cancer	4.75e-05	0.00086	CcSEcCtD
Etoricoxib—Hypoaesthesia—Docetaxel—skin cancer	4.73e-05	0.000855	CcSEcCtD
Etoricoxib—MAPK14—MAPK Signaling Pathway—RASA1—skin cancer	4.73e-05	0.00594	CbGpPWpGaD
Etoricoxib—Confusional state—Fluorouracil—skin cancer	4.72e-05	0.000853	CcSEcCtD
Etoricoxib—Pharyngitis—Docetaxel—skin cancer	4.72e-05	0.000853	CcSEcCtD
Etoricoxib—Urinary tract disorder—Docetaxel—skin cancer	4.69e-05	0.000849	CcSEcCtD
Etoricoxib—Oedema peripheral—Docetaxel—skin cancer	4.68e-05	0.000847	CcSEcCtD
Etoricoxib—Anaphylactic shock—Fluorouracil—skin cancer	4.68e-05	0.000846	CcSEcCtD
Etoricoxib—Oedema—Fluorouracil—skin cancer	4.68e-05	0.000846	CcSEcCtD
Etoricoxib—Connective tissue disorder—Docetaxel—skin cancer	4.67e-05	0.000845	CcSEcCtD
Etoricoxib—Urethral disorder—Docetaxel—skin cancer	4.66e-05	0.000843	CcSEcCtD
Etoricoxib—MAPK14—Nanoparticle-mediated activation of receptor signaling—KRAS—skin cancer	4.65e-05	0.00584	CbGpPWpGaD
Etoricoxib—Infection—Fluorouracil—skin cancer	4.65e-05	0.000841	CcSEcCtD
Etoricoxib—MAPK14—Trk receptor signaling mediated by the MAPK pathway—NRAS—skin cancer	4.63e-05	0.00581	CbGpPWpGaD
Etoricoxib—MAPK14—Signalling to RAS—NRAS—skin cancer	4.63e-05	0.00581	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Dactinomycin—skin cancer	4.63e-05	0.000837	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Temozolomide—skin cancer	4.63e-05	0.000837	CcSEcCtD
Etoricoxib—Insomnia—Temozolomide—skin cancer	4.59e-05	0.000831	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Dactinomycin—skin cancer	4.59e-05	0.00083	CcSEcCtD
Etoricoxib—Nervous system disorder—Fluorouracil—skin cancer	4.59e-05	0.00083	CcSEcCtD
Etoricoxib—Thrombocytopenia—Fluorouracil—skin cancer	4.58e-05	0.000829	CcSEcCtD
Etoricoxib—Visual impairment—Docetaxel—skin cancer	4.58e-05	0.000828	CcSEcCtD
Etoricoxib—Dyspnoea—Temozolomide—skin cancer	4.53e-05	0.000819	CcSEcCtD
Etoricoxib—MAPK14—MAPK Cascade—KRAS—skin cancer	4.52e-05	0.00568	CbGpPWpGaD
Etoricoxib—Somnolence—Temozolomide—skin cancer	4.51e-05	0.000816	CcSEcCtD
Etoricoxib—Erythema multiforme—Docetaxel—skin cancer	4.49e-05	0.000813	CcSEcCtD
Etoricoxib—Dyspepsia—Temozolomide—skin cancer	4.47e-05	0.000808	CcSEcCtD
Etoricoxib—Anorexia—Fluorouracil—skin cancer	4.46e-05	0.000807	CcSEcCtD
Etoricoxib—Eye disorder—Docetaxel—skin cancer	4.44e-05	0.000803	CcSEcCtD
Etoricoxib—Abdominal pain—Dactinomycin—skin cancer	4.44e-05	0.000803	CcSEcCtD
Etoricoxib—Hypersensitivity—Bleomycin—skin cancer	4.44e-05	0.000802	CcSEcCtD
Etoricoxib—Decreased appetite—Temozolomide—skin cancer	4.41e-05	0.000798	CcSEcCtD
Etoricoxib—Cardiac disorder—Docetaxel—skin cancer	4.41e-05	0.000798	CcSEcCtD
Etoricoxib—Flushing—Docetaxel—skin cancer	4.41e-05	0.000798	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Temozolomide—skin cancer	4.38e-05	0.000793	CcSEcCtD
Etoricoxib—Fatigue—Temozolomide—skin cancer	4.38e-05	0.000792	CcSEcCtD
Etoricoxib—Pain—Temozolomide—skin cancer	4.34e-05	0.000785	CcSEcCtD
Etoricoxib—Constipation—Temozolomide—skin cancer	4.34e-05	0.000785	CcSEcCtD
Etoricoxib—MAPK14—TSH signaling pathway—BRAF—skin cancer	4.33e-05	0.00544	CbGpPWpGaD
Etoricoxib—Asthenia—Bleomycin—skin cancer	4.32e-05	0.000781	CcSEcCtD
Etoricoxib—Angiopathy—Docetaxel—skin cancer	4.31e-05	0.00078	CcSEcCtD
Etoricoxib—Immune system disorder—Docetaxel—skin cancer	4.29e-05	0.000777	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	4.29e-05	0.00539	CbGpPWpGaD
Etoricoxib—Mediastinal disorder—Docetaxel—skin cancer	4.28e-05	0.000775	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Fluorouracil—skin cancer	4.26e-05	0.000771	CcSEcCtD
Etoricoxib—Pruritus—Bleomycin—skin cancer	4.26e-05	0.00077	CcSEcCtD
Etoricoxib—Arrhythmia—Docetaxel—skin cancer	4.25e-05	0.000768	CcSEcCtD
Etoricoxib—MAPK14—CXCR3-mediated signaling events—NRAS—skin cancer	4.23e-05	0.00532	CbGpPWpGaD
Etoricoxib—Insomnia—Fluorouracil—skin cancer	4.23e-05	0.000765	CcSEcCtD
Etoricoxib—MAPK14—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—skin cancer	4.23e-05	0.00531	CbGpPWpGaD
Etoricoxib—Alopecia—Docetaxel—skin cancer	4.2e-05	0.00076	CcSEcCtD
Etoricoxib—Feeling abnormal—Temozolomide—skin cancer	4.18e-05	0.000757	CcSEcCtD
Etoricoxib—Dyspnoea—Fluorouracil—skin cancer	4.17e-05	0.000754	CcSEcCtD
Etoricoxib—Mental disorder—Docetaxel—skin cancer	4.16e-05	0.000753	CcSEcCtD
Etoricoxib—Somnolence—Fluorouracil—skin cancer	4.16e-05	0.000752	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Temozolomide—skin cancer	4.15e-05	0.000751	CcSEcCtD
Etoricoxib—Malnutrition—Docetaxel—skin cancer	4.14e-05	0.000748	CcSEcCtD
Etoricoxib—Erythema—Docetaxel—skin cancer	4.14e-05	0.000748	CcSEcCtD
Etoricoxib—Hypersensitivity—Dactinomycin—skin cancer	4.14e-05	0.000748	CcSEcCtD
Etoricoxib—MAPK14—CDC42 signaling events—BRAF—skin cancer	4.13e-05	0.00519	CbGpPWpGaD
Etoricoxib—Dyspepsia—Fluorouracil—skin cancer	4.12e-05	0.000745	CcSEcCtD
Etoricoxib—MAPK14—p53 pathway—CDKN2A—skin cancer	4.09e-05	0.00514	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	4.07e-05	0.00511	CbGpPWpGaD
Etoricoxib—Decreased appetite—Fluorouracil—skin cancer	4.07e-05	0.000736	CcSEcCtD
Etoricoxib—Dysgeusia—Docetaxel—skin cancer	4.05e-05	0.000733	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Fluorouracil—skin cancer	4.04e-05	0.000731	CcSEcCtD
Etoricoxib—Urticaria—Temozolomide—skin cancer	4.03e-05	0.00073	CcSEcCtD
Etoricoxib—Asthenia—Dactinomycin—skin cancer	4.03e-05	0.000729	CcSEcCtD
Etoricoxib—Abdominal pain—Temozolomide—skin cancer	4.01e-05	0.000726	CcSEcCtD
Etoricoxib—Pain—Fluorouracil—skin cancer	4e-05	0.000724	CcSEcCtD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—FOXO4—skin cancer	3.99e-05	0.00501	CbGpPWpGaD
Etoricoxib—MAPK14—Trk receptor signaling mediated by the MAPK pathway—KRAS—skin cancer	3.98e-05	0.005	CbGpPWpGaD
Etoricoxib—MAPK14—Signalling to RAS—KRAS—skin cancer	3.98e-05	0.005	CbGpPWpGaD
Etoricoxib—Muscle spasms—Docetaxel—skin cancer	3.98e-05	0.000719	CcSEcCtD
Etoricoxib—MAPK14—Nanoparticle-mediated activation of receptor signaling—HRAS—skin cancer	3.95e-05	0.00497	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—skin cancer	3.9e-05	0.0049	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Fluorouracil—skin cancer	3.86e-05	0.000697	CcSEcCtD
Etoricoxib—MAPK14—MAPK Cascade—HRAS—skin cancer	3.84e-05	0.00483	CbGpPWpGaD
Etoricoxib—Diarrhoea—Dactinomycin—skin cancer	3.84e-05	0.000695	CcSEcCtD
Etoricoxib—Vomiting—Bleomycin—skin cancer	3.83e-05	0.000692	CcSEcCtD
Etoricoxib—Anaemia—Docetaxel—skin cancer	3.82e-05	0.000692	CcSEcCtD
Etoricoxib—Rash—Bleomycin—skin cancer	3.8e-05	0.000686	CcSEcCtD
Etoricoxib—Dermatitis—Bleomycin—skin cancer	3.79e-05	0.000686	CcSEcCtD
Etoricoxib—MAPK14—Signalling to ERKs—NRAS—skin cancer	3.76e-05	0.00473	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Temozolomide—skin cancer	3.74e-05	0.000677	CcSEcCtD
Etoricoxib—MAPK14—Regulation of retinoblastoma protein—CDKN2A—skin cancer	3.74e-05	0.0047	CbGpPWpGaD
Etoricoxib—Urticaria—Fluorouracil—skin cancer	3.72e-05	0.000672	CcSEcCtD
Etoricoxib—Palpitations—Docetaxel—skin cancer	3.66e-05	0.000661	CcSEcCtD
Etoricoxib—MAPK14—CXCR3-mediated signaling events—KRAS—skin cancer	3.64e-05	0.00458	CbGpPWpGaD
Etoricoxib—Asthenia—Temozolomide—skin cancer	3.64e-05	0.000659	CcSEcCtD
Etoricoxib—Cough—Docetaxel—skin cancer	3.61e-05	0.000653	CcSEcCtD
Etoricoxib—Pruritus—Temozolomide—skin cancer	3.59e-05	0.00065	CcSEcCtD
Etoricoxib—Nausea—Bleomycin—skin cancer	3.58e-05	0.000647	CcSEcCtD
Etoricoxib—Hypertension—Docetaxel—skin cancer	3.57e-05	0.000646	CcSEcCtD
Etoricoxib—Vomiting—Dactinomycin—skin cancer	3.57e-05	0.000646	CcSEcCtD
Etoricoxib—MAPK14—EPO signaling pathway—HRAS—skin cancer	3.55e-05	0.00446	CbGpPWpGaD
Etoricoxib—Rash—Dactinomycin—skin cancer	3.54e-05	0.00064	CcSEcCtD
Etoricoxib—Chest pain—Docetaxel—skin cancer	3.52e-05	0.000637	CcSEcCtD
Etoricoxib—Arthralgia—Docetaxel—skin cancer	3.52e-05	0.000637	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	3.5e-05	0.000633	CcSEcCtD
Etoricoxib—Diarrhoea—Temozolomide—skin cancer	3.47e-05	0.000628	CcSEcCtD
Etoricoxib—MAPK14—Developmental Biology—SCN10A—skin cancer	3.47e-05	0.00436	CbGpPWpGaD
Etoricoxib—MAPK14—Alpha 6 Beta 4 signaling pathway—HRAS—skin cancer	3.47e-05	0.00435	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	3.46e-05	0.00434	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Fluorouracil—skin cancer	3.45e-05	0.000623	CcSEcCtD
Etoricoxib—Dry mouth—Docetaxel—skin cancer	3.45e-05	0.000623	CcSEcCtD
Etoricoxib—Confusional state—Docetaxel—skin cancer	3.4e-05	0.000616	CcSEcCtD
Etoricoxib—MAPK14—Trk receptor signaling mediated by the MAPK pathway—HRAS—skin cancer	3.39e-05	0.00425	CbGpPWpGaD
Etoricoxib—MAPK14—p38 MAPK Signaling Pathway—HRAS—skin cancer	3.39e-05	0.00425	CbGpPWpGaD
Etoricoxib—MAPK14—Signalling to RAS—HRAS—skin cancer	3.39e-05	0.00425	CbGpPWpGaD
Etoricoxib—Oedema—Docetaxel—skin cancer	3.38e-05	0.000611	CcSEcCtD
Etoricoxib—Anaphylactic shock—Docetaxel—skin cancer	3.38e-05	0.000611	CcSEcCtD
Etoricoxib—Dizziness—Temozolomide—skin cancer	3.36e-05	0.000607	CcSEcCtD
Etoricoxib—Infection—Docetaxel—skin cancer	3.35e-05	0.000607	CcSEcCtD
Etoricoxib—Nausea—Dactinomycin—skin cancer	3.33e-05	0.000603	CcSEcCtD
Etoricoxib—Shock—Docetaxel—skin cancer	3.32e-05	0.000601	CcSEcCtD
Etoricoxib—MAPK14—Corticotropin-releasing hormone—BRAF—skin cancer	3.32e-05	0.00417	CbGpPWpGaD
Etoricoxib—Nervous system disorder—Docetaxel—skin cancer	3.31e-05	0.000599	CcSEcCtD
Etoricoxib—Pruritus—Fluorouracil—skin cancer	3.31e-05	0.000599	CcSEcCtD
Etoricoxib—Thrombocytopenia—Docetaxel—skin cancer	3.31e-05	0.000598	CcSEcCtD
Etoricoxib—PTGS2—Overview of nanoparticle effects—IL6—skin cancer	3.3e-05	0.00414	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—FOXO4—skin cancer	3.29e-05	0.00414	CbGpPWpGaD
Etoricoxib—Skin disorder—Docetaxel—skin cancer	3.28e-05	0.000593	CcSEcCtD
Etoricoxib—MAPK14—Signalling to ERKs—KRAS—skin cancer	3.24e-05	0.00407	CbGpPWpGaD
Etoricoxib—MAPK14—Signalling to RAS—IL6—skin cancer	3.24e-05	0.00407	CbGpPWpGaD
Etoricoxib—MAPK14—Amyotrophic lateral sclerosis (ALS)—TP53—skin cancer	3.24e-05	0.00407	CbGpPWpGaD
Etoricoxib—Vomiting—Temozolomide—skin cancer	3.23e-05	0.000584	CcSEcCtD
Etoricoxib—Anorexia—Docetaxel—skin cancer	3.22e-05	0.000582	CcSEcCtD
Etoricoxib—Rash—Temozolomide—skin cancer	3.2e-05	0.000579	CcSEcCtD
Etoricoxib—Diarrhoea—Fluorouracil—skin cancer	3.2e-05	0.000579	CcSEcCtD
Etoricoxib—Dermatitis—Temozolomide—skin cancer	3.2e-05	0.000579	CcSEcCtD
Etoricoxib—MAPK14—IL2-mediated signaling events—NRAS—skin cancer	3.2e-05	0.00401	CbGpPWpGaD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—BRAF—skin cancer	3.18e-05	0.004	CbGpPWpGaD
Etoricoxib—Headache—Temozolomide—skin cancer	3.18e-05	0.000575	CcSEcCtD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—TERT—skin cancer	3.14e-05	0.00395	CbGpPWpGaD
Etoricoxib—MAPK14—CXCR3-mediated signaling events—HRAS—skin cancer	3.1e-05	0.00389	CbGpPWpGaD
Etoricoxib—Dizziness—Fluorouracil—skin cancer	3.09e-05	0.00056	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Docetaxel—skin cancer	3.08e-05	0.000556	CcSEcCtD
Etoricoxib—MAPK14—Oxidative Stress Induced Senescence—CDK4—skin cancer	3.05e-05	0.00384	CbGpPWpGaD
Etoricoxib—Insomnia—Docetaxel—skin cancer	3.05e-05	0.000552	CcSEcCtD
Etoricoxib—Nausea—Temozolomide—skin cancer	3.02e-05	0.000546	CcSEcCtD
Etoricoxib—Dyspnoea—Docetaxel—skin cancer	3.01e-05	0.000545	CcSEcCtD
Etoricoxib—Somnolence—Docetaxel—skin cancer	3e-05	0.000543	CcSEcCtD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—BRAF—skin cancer	2.99e-05	0.00375	CbGpPWpGaD
Etoricoxib—Vomiting—Fluorouracil—skin cancer	2.97e-05	0.000538	CcSEcCtD
Etoricoxib—Dyspepsia—Docetaxel—skin cancer	2.97e-05	0.000538	CcSEcCtD
Etoricoxib—Rash—Fluorouracil—skin cancer	2.95e-05	0.000534	CcSEcCtD
Etoricoxib—Dermatitis—Fluorouracil—skin cancer	2.95e-05	0.000533	CcSEcCtD
Etoricoxib—Decreased appetite—Docetaxel—skin cancer	2.94e-05	0.000531	CcSEcCtD
Etoricoxib—Headache—Fluorouracil—skin cancer	2.93e-05	0.00053	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Docetaxel—skin cancer	2.92e-05	0.000527	CcSEcCtD
Etoricoxib—Fatigue—Docetaxel—skin cancer	2.91e-05	0.000527	CcSEcCtD
Etoricoxib—Pain—Docetaxel—skin cancer	2.89e-05	0.000522	CcSEcCtD
Etoricoxib—Constipation—Docetaxel—skin cancer	2.89e-05	0.000522	CcSEcCtD
Etoricoxib—MAPK14—Innate Immune System—TLR7—skin cancer	2.8e-05	0.00352	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Docetaxel—skin cancer	2.78e-05	0.000503	CcSEcCtD
Etoricoxib—Nausea—Fluorouracil—skin cancer	2.78e-05	0.000503	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Docetaxel—skin cancer	2.76e-05	0.000499	CcSEcCtD
Etoricoxib—MAPK14—Signalling to ERKs—HRAS—skin cancer	2.75e-05	0.00346	CbGpPWpGaD
Etoricoxib—MAPK14—IL2-mediated signaling events—KRAS—skin cancer	2.75e-05	0.00345	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	2.74e-05	0.00344	CbGpPWpGaD
Etoricoxib—MAPK14—TWEAK Signaling Pathway—IL6—skin cancer	2.74e-05	0.00344	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—NRAS—skin cancer	2.69e-05	0.00338	CbGpPWpGaD
Etoricoxib—Abdominal pain—Docetaxel—skin cancer	2.67e-05	0.000483	CcSEcCtD
Etoricoxib—MAPK14—Signaling Pathways—RHOU—skin cancer	2.65e-05	0.00333	CbGpPWpGaD
Etoricoxib—MAPK14—Signalling to ERKs—IL6—skin cancer	2.64e-05	0.00331	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	2.6e-05	0.00327	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—CDKN2A—skin cancer	2.58e-05	0.00324	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—FOXO4—skin cancer	2.53e-05	0.00318	CbGpPWpGaD
Etoricoxib—MAPK14—TSLP Signaling Pathway—IL6—skin cancer	2.5e-05	0.00314	CbGpPWpGaD
Etoricoxib—MAPK14—IL6-mediated signaling events—IL6—skin cancer	2.5e-05	0.00314	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Docetaxel—skin cancer	2.49e-05	0.00045	CcSEcCtD
Etoricoxib—Asthenia—Docetaxel—skin cancer	2.42e-05	0.000438	CcSEcCtD
Etoricoxib—Pruritus—Docetaxel—skin cancer	2.39e-05	0.000432	CcSEcCtD
Etoricoxib—MAPK14—Oncostatin M Signaling Pathway—KRAS—skin cancer	2.37e-05	0.00298	CbGpPWpGaD
Etoricoxib—MAPK14—IL2-mediated signaling events—HRAS—skin cancer	2.34e-05	0.00294	CbGpPWpGaD
Etoricoxib—MAPK14—Oxidative Stress Induced Senescence—CDKN2A—skin cancer	2.33e-05	0.00293	CbGpPWpGaD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	2.32e-05	0.00292	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—KRAS—skin cancer	2.31e-05	0.00291	CbGpPWpGaD
Etoricoxib—Diarrhoea—Docetaxel—skin cancer	2.31e-05	0.000418	CcSEcCtD
Etoricoxib—MAPK14—p53 pathway—TP53—skin cancer	2.28e-05	0.00286	CbGpPWpGaD
Etoricoxib—Dizziness—Docetaxel—skin cancer	2.23e-05	0.000404	CcSEcCtD
Etoricoxib—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	2.21e-05	0.00278	CbGpPWpGaD
Etoricoxib—MAPK14—Kit receptor signaling pathway—HRAS—skin cancer	2.18e-05	0.00274	CbGpPWpGaD
Etoricoxib—MAPK14—MAP kinase activation in TLR cascade—IL6—skin cancer	2.17e-05	0.00273	CbGpPWpGaD
Etoricoxib—Vomiting—Docetaxel—skin cancer	2.15e-05	0.000388	CcSEcCtD
Etoricoxib—MAPK14—Cellular Senescence—CDK4—skin cancer	2.14e-05	0.00268	CbGpPWpGaD
Etoricoxib—Rash—Docetaxel—skin cancer	2.13e-05	0.000385	CcSEcCtD
Etoricoxib—Dermatitis—Docetaxel—skin cancer	2.13e-05	0.000385	CcSEcCtD
Etoricoxib—Headache—Docetaxel—skin cancer	2.12e-05	0.000383	CcSEcCtD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—BRAF—skin cancer	2.11e-05	0.00265	CbGpPWpGaD
Etoricoxib—MAPK14—Oncostatin M Signaling Pathway—TP53—skin cancer	2.11e-05	0.00265	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	2.09e-05	0.00263	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.09e-05	0.00263	CbGpPWpGaD
Etoricoxib—MAPK14—ATF-2 transcription factor network—IL6—skin cancer	2.08e-05	0.00262	CbGpPWpGaD
Etoricoxib—MAPK14—Endothelins—HRAS—skin cancer	2.07e-05	0.0026	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—TP53—skin cancer	2.06e-05	0.00258	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—BRAF—skin cancer	2.05e-05	0.00258	CbGpPWpGaD
Etoricoxib—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	2.03e-05	0.00255	CbGpPWpGaD
Etoricoxib—MAPK14—Oncostatin M Signaling Pathway—HRAS—skin cancer	2.02e-05	0.00253	CbGpPWpGaD
Etoricoxib—Nausea—Docetaxel—skin cancer	2.01e-05	0.000363	CcSEcCtD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	2e-05	0.00251	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—RASA1—skin cancer	1.99e-05	0.00251	CbGpPWpGaD
Etoricoxib—MAPK14—TSH signaling pathway—HRAS—skin cancer	1.99e-05	0.0025	CbGpPWpGaD
Etoricoxib—PTGS2—C-MYB transcription factor network—CDKN2A—skin cancer	1.97e-05	0.00248	CbGpPWpGaD
Etoricoxib—MAPK14—BCR signaling pathway—HRAS—skin cancer	1.97e-05	0.00247	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—HRAS—skin cancer	1.97e-05	0.00247	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—CDK4—skin cancer	1.96e-05	0.00247	CbGpPWpGaD
Etoricoxib—MAPK14—CDC42 signaling events—HRAS—skin cancer	1.9e-05	0.00239	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—NRAS—skin cancer	1.85e-05	0.00232	CbGpPWpGaD
Etoricoxib—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	1.85e-05	0.00232	CbGpPWpGaD
Etoricoxib—MAPK14—Leptin signaling pathway—HRAS—skin cancer	1.8e-05	0.00226	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—TP53—skin cancer	1.75e-05	0.0022	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by VEGF—NRAS—skin cancer	1.75e-05	0.00219	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—BRAF—skin cancer	1.74e-05	0.00219	CbGpPWpGaD
Etoricoxib—MAPK14—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—skin cancer	1.72e-05	0.00216	CbGpPWpGaD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	1.7e-05	0.00213	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	1.69e-05	0.00212	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—TLR7—skin cancer	1.63e-05	0.00205	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular Senescence—CDKN2A—skin cancer	1.63e-05	0.00205	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—CDK4—skin cancer	1.61e-05	0.00203	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—IL6—skin cancer	1.6e-05	0.00201	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	1.59e-05	0.002	CbGpPWpGaD
Etoricoxib—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	1.58e-05	0.00198	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88 cascade initiated on plasma membrane—IL6—skin cancer	1.56e-05	0.00196	CbGpPWpGaD
Etoricoxib—MAPK14—TCR Signaling Pathway—HRAS—skin cancer	1.55e-05	0.00195	CbGpPWpGaD
Etoricoxib—MAPK14—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—skin cancer	1.54e-05	0.00194	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.52e-05	0.00191	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88 dependent cascade initiated on endosome—IL6—skin cancer	1.51e-05	0.0019	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by VEGF—KRAS—skin cancer	1.5e-05	0.00189	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	1.5e-05	0.00188	CbGpPWpGaD
Etoricoxib—MAPK14—TCR Signaling Pathway—IL6—skin cancer	1.49e-05	0.00187	CbGpPWpGaD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—HRAS—skin cancer	1.46e-05	0.00184	CbGpPWpGaD
Etoricoxib—MAPK14—Toll Like Receptor 9 (TLR9) Cascade—IL6—skin cancer	1.46e-05	0.00184	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—FOXO4—skin cancer	1.44e-05	0.00181	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—IL6—skin cancer	1.44e-05	0.0018	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—TP53—skin cancer	1.44e-05	0.0018	CbGpPWpGaD
Etoricoxib—PTGS2—C-MYB transcription factor network—NRAS—skin cancer	1.43e-05	0.0018	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.38e-05	0.00174	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88-independent cascade—IL6—skin cancer	1.38e-05	0.00173	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—HRAS—skin cancer	1.37e-05	0.00173	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	1.35e-05	0.0017	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—IL6—skin cancer	1.35e-05	0.00169	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—BRAF—skin cancer	1.34e-05	0.00168	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.34e-05	0.00168	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—IL6—skin cancer	1.31e-05	0.00165	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	1.31e-05	0.00165	CbGpPWpGaD
Etoricoxib—MAPK14—Oxidative Stress Induced Senescence—TP53—skin cancer	1.3e-05	0.00163	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTCH2—skin cancer	1.3e-05	0.00163	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—IL6—skin cancer	1.29e-05	0.00163	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—NRAS—skin cancer	1.29e-05	0.00162	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by VEGF—HRAS—skin cancer	1.28e-05	0.0016	CbGpPWpGaD
Etoricoxib—MAPK14—Activated TLR4 signalling—IL6—skin cancer	1.24e-05	0.00156	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—CDKN2A—skin cancer	1.23e-05	0.00155	CbGpPWpGaD
Etoricoxib—PTGS2—C-MYB transcription factor network—KRAS—skin cancer	1.23e-05	0.00155	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by VEGF—IL6—skin cancer	1.22e-05	0.00154	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—TP53—skin cancer	1.2e-05	0.0015	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.18e-05	0.00149	CbGpPWpGaD
Etoricoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—IL6—skin cancer	1.17e-05	0.00146	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—KRAS—skin cancer	1.14e-05	0.00143	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	1.13e-05	0.00142	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—KRAS—skin cancer	1.11e-05	0.00139	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	1.09e-05	0.00138	CbGpPWpGaD
Etoricoxib—MAPK14—BDNF signaling pathway—HRAS—skin cancer	1.07e-05	0.00134	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IL6—skin cancer	1.05e-05	0.00132	CbGpPWpGaD
Etoricoxib—PTGS2—C-MYB transcription factor network—HRAS—skin cancer	1.05e-05	0.00132	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—IL6—skin cancer	1.04e-05	0.0013	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1e-05	0.00126	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TP53—skin cancer	9.86e-06	0.00124	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—GLI2—skin cancer	9.82e-06	0.00123	CbGpPWpGaD
Etoricoxib—MAPK14—Insulin Signaling—HRAS—skin cancer	9.81e-06	0.00123	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—CDK4—skin cancer	9.78e-06	0.00123	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—HRAS—skin cancer	9.71e-06	0.00122	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—IL6—skin cancer	9.67e-06	0.00121	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	9.61e-06	0.00121	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	9.42e-06	0.00118	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MC1R—skin cancer	9.37e-06	0.00118	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PLIN2—skin cancer	9.31e-06	0.00117	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—GLI1—skin cancer	9.23e-06	0.00116	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular Senescence—TP53—skin cancer	9.09e-06	0.00114	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CSPG4—skin cancer	8.96e-06	0.00113	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	8.9e-06	0.00112	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PLIN2—skin cancer	8.76e-06	0.0011	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SUFU—skin cancer	8.75e-06	0.0011	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—NRAS—skin cancer	8.42e-06	0.00106	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—FOXO4—skin cancer	8.42e-06	0.00106	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—TP53—skin cancer	8.36e-06	0.00105	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular Senescence—IL6—skin cancer	8.32e-06	0.00104	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	8.01e-06	0.00101	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	7.67e-06	0.000963	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—IL6—skin cancer	7.65e-06	0.000961	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CSPG4—skin cancer	7.5e-06	0.000942	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—KRAS—skin cancer	7.25e-06	0.00091	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CSPG4—skin cancer	7.06e-06	0.000887	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—TP53—skin cancer	6.87e-06	0.000863	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PLIN2—skin cancer	6.76e-06	0.000849	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SHH—skin cancer	6.67e-06	0.000838	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—RASA1—skin cancer	6.63e-06	0.000833	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	6.4e-06	0.000803	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTCH1—skin cancer	6.33e-06	0.000795	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SMO—skin cancer	6.33e-06	0.000795	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—IL6—skin cancer	6.29e-06	0.00079	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PLIN2—skin cancer	6.22e-06	0.000781	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PLIN2—skin cancer	6.16e-06	0.000774	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—HRAS—skin cancer	6.16e-06	0.000774	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTGER4—skin cancer	6.16e-06	0.000774	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ENO2—skin cancer	6.09e-06	0.000765	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SHH—skin cancer	6.09e-06	0.000765	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—ERCC2—skin cancer	5.96e-06	0.000749	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—IL6—skin cancer	5.9e-06	0.000741	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	5.68e-06	0.000714	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CSPG4—skin cancer	5.45e-06	0.000684	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FOXO4—skin cancer	5.44e-06	0.000683	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—NRAS—skin cancer	5.44e-06	0.000683	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—NRAS—skin cancer	5.34e-06	0.00067	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PLIN2—skin cancer	5.27e-06	0.000662	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ENO2—skin cancer	5.1e-06	0.000641	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CSPG4—skin cancer	5.01e-06	0.000629	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CSPG4—skin cancer	4.97e-06	0.000624	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—FOXO4—skin cancer	4.96e-06	0.000624	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—NRAS—skin cancer	4.8e-06	0.000603	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ENO2—skin cancer	4.8e-06	0.000603	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—KRAS—skin cancer	4.68e-06	0.000588	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—KRAS—skin cancer	4.59e-06	0.000577	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CSPG4—skin cancer	4.25e-06	0.000533	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—KRAS—skin cancer	4.13e-06	0.000519	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TP53—skin cancer	4.08e-06	0.000513	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PLIN2—skin cancer	4.06e-06	0.000511	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—HRAS—skin cancer	3.98e-06	0.0005	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—HRAS—skin cancer	3.9e-06	0.00049	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—IL6—skin cancer	3.81e-06	0.000478	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ENO2—skin cancer	3.7e-06	0.000465	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TERT—skin cancer	3.63e-06	0.000456	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ERCC2—skin cancer	3.54e-06	0.000444	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—HRAS—skin cancer	3.51e-06	0.000441	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ENO2—skin cancer	3.41e-06	0.000428	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ENO2—skin cancer	3.38e-06	0.000424	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—IL6—skin cancer	3.36e-06	0.000422	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TERT—skin cancer	3.32e-06	0.000416	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CSPG4—skin cancer	3.28e-06	0.000412	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ERCC2—skin cancer	2.96e-06	0.000372	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.9e-06	0.000364	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ENO2—skin cancer	2.89e-06	0.000362	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—BRAF—skin cancer	2.88e-06	0.000362	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NRAS—skin cancer	2.8e-06	0.000351	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ERCC2—skin cancer	2.79e-06	0.00035	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.64e-06	0.000332	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—BRAF—skin cancer	2.63e-06	0.00033	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—KRAS—skin cancer	2.41e-06	0.000302	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.26e-06	0.000283	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ENO2—skin cancer	2.23e-06	0.00028	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ERCC2—skin cancer	2.15e-06	0.00027	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HRAS—skin cancer	2.05e-06	0.000257	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ERCC2—skin cancer	1.98e-06	0.000249	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ERCC2—skin cancer	1.96e-06	0.000246	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL6—skin cancer	1.96e-06	0.000246	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NRAS—skin cancer	1.81e-06	0.000227	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ERCC2—skin cancer	1.68e-06	0.000211	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTGS2—skin cancer	1.67e-06	0.00021	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NRAS—skin cancer	1.65e-06	0.000207	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KRAS—skin cancer	1.56e-06	0.000196	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KRAS—skin cancer	1.42e-06	0.000178	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—skin cancer	1.38e-06	0.000174	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HRAS—skin cancer	1.32e-06	0.000166	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ERCC2—skin cancer	1.29e-06	0.000162	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTGS2—skin cancer	1.29e-06	0.000162	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL6—skin cancer	1.27e-06	0.000159	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HRAS—skin cancer	1.21e-06	0.000152	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTGS2—skin cancer	1.19e-06	0.000149	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTGS2—skin cancer	1.18e-06	0.000148	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—IL6—skin cancer	1.16e-06	0.000145	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTGS2—skin cancer	1.01e-06	0.000126	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTGS2—skin cancer	7.76e-07	9.74e-05	CbGpPWpGaD
